Dr. Patel is an expert in the treatment of myeloproliferative neoplasms, myelodysplastic syndromes, and leukemia. He is an active researcher whose work is focused on the development of clinical trials to investigate novel therapies that may improve the standard of care for patients with myeloid cancers and leukemia. Dr. Patel has published his research in several well-respected peer-reviewed journals including Blood, Blood Advances, the British Journal of Haematology, Cancer, JCI Insight, and Bone Marrow Transplantation.
University of Chicago
Chicago, IL
Fellowship - Hematology-Oncology
2021
McGaw Medical Center of Northwestern University
Chicago, IL
Chief Residency - Internal Medicine
2018
McGaw Medical Center of Northwestern University
Chicago, IL
Residency - Internal Medicine
2017
University of Missouri School of Medicine
Columbia, MO
MD - Medicine
2014
Northwestern University
Evanston, IL
BA - Economics
2010
Real-world treatment and outcomes in hairy cell leukemia: a multicenter retrospective cohort including BRAF inhibitor therapy.
Real-world treatment and outcomes in hairy cell leukemia: a multicenter retrospective cohort including BRAF inhibitor therapy. Leuk Lymphoma. 2026 Jun 11; 1-9.
PMID: 42281276
NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026.
NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026. J Natl Compr Canc Netw. 2026 Jun; 24(6):222-229.
PMID: 42297017
Cardiovascular Events in Patients With Acute Myeloid Leukemia Treated With Venetoclax: A Multicenter Cohort Study.
Cardiovascular Events in Patients With Acute Myeloid Leukemia Treated With Venetoclax: A Multicenter Cohort Study. JACC Adv. 2026 Jun; 5(6 Pt 2):102821.
PMID: 42312783
Exercises in Clinical Reasoning: Applying High-Value Care When the Counts Don't Add Up.
Exercises in Clinical Reasoning: Applying High-Value Care When the Counts Don't Add Up. J Gen Intern Med. 2026 Apr 20.
PMID: 42010105
Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leuk Lymphoma. 2026 Apr 09; 1-8.
PMID: 41954351
Echocardiographic high-output heart failure is associated with worse survival among patients with myelofibrosis.
Echocardiographic high-output heart failure is associated with worse survival among patients with myelofibrosis. Cardiooncology. 2026 Mar 11.
PMID: 41814386
Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias.
Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias. Blood Adv. 2026 Mar 10; 10(5):1746-1755.
PMID: 41499760
Impact of statin use on cardiovascular and hematologic outcomes among patients with myeloproliferative neoplasms.
Impact of statin use on cardiovascular and hematologic outcomes among patients with myeloproliferative neoplasms. Blood Adv. 2026 Mar 10; 10(5):1603-1613.
PMID: 41499780
Ruxolitinib and heart failure outcomes among patients with myelofibrosis.
Ruxolitinib and heart failure outcomes among patients with myelofibrosis. Leuk Lymphoma. 2026 Mar 05; 1-8.
PMID: 41784313
Targeting menin in T-lineage acute lymphoblastic leukemia.
Targeting menin in T-lineage acute lymphoblastic leukemia. Mol Cancer Ther. 2026 Mar 04.
PMID: 41778833